Resona Asset Management Co. Ltd. Has $144.06 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Resona Asset Management Co. Ltd. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 7.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 870,420 shares of the company’s stock after acquiring an additional 58,973 shares during the period. Johnson & Johnson comprises 0.8% of Resona Asset Management Co. Ltd.’s investment portfolio, making the stock its 18th biggest holding. Resona Asset Management Co. Ltd.’s holdings in Johnson & Johnson were worth $144,062,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after buying an additional 1,170,120 shares during the last quarter. Northern Trust Corp increased its stake in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after buying an additional 3,363,235 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after buying an additional 4,842,582 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after buying an additional 712,181 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after buying an additional 448,666 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.4%

JNJ opened at $173.98 on Tuesday. The company has a 50 day moving average of $159.63 and a 200 day moving average of $157.79. The company has a market cap of $418.99 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 2.21 and a beta of 0.41. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $174.60. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. Johnson & Johnson’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Bank of America increased their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research note on Thursday, July 17th. Guggenheim restated a “neutral” rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. UBS Group raised their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 17th. Finally, Raymond James Financial decreased their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Nine equities research analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.